AOP Health Presents Final Results From Its CONTINUATION-PV Study – up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients – at EHA 2022 Annual Meeting
VIENNA–(BUSINESS WIRE)–#MPN–AOP Health announced the final results on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from its CONTINUATION-PV study in an oral presentation at the prestigious EHA (European Hematology Association) 2022 Annual Meeting by Professor Heinz Gisslinger, Medical University of Vienna, Austria 1. Link to abstract Ropeginterferon alfa-2b is a long-acting, mono-pegylated proline interferon … [Read more…]
